Search
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsRogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Categories: Heterocyclic Compounds, 1-RingTroriluzole
go.drugbank.com/drugs/DB15079InvestigationalTroriluzole is under investigation in clinical trial NCT03701399 (Troriluzole in Adult Subjects With Spinocerebellar Ataxia).
Gefapixant
go.drugbank.com/drugs/DB15097ApprovedIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … [L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough.
Categories: MATE 1 Substrates, MATE 2 SubstratesRSV-604
go.drugbank.com/drugs/DB15197InvestigationalRSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Categories: Heterocyclic Compounds, 2-RingAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. … [L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-Abivertinib
go.drugbank.com/drugs/DB15327Investigational[L17388,L17393] The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple … Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).
Categories: Heterocyclic Compounds, 1-RingBalcinrenone
go.drugbank.com/drugs/DB15418InvestigationalAZD-9977 is under investigation in clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers).
Categories: Heterocyclic Compounds, 1-RingBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers.
Categories: MATE 2 Inhibitors, Cytochrome P-450 SubstratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one, Kras G12C inhibitor 9